Literature DB >> 19496647

Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns.

Khetam Hussein1, Hanna Sprecher, Tania Mashiach, Ilana Oren, Imad Kassis, Renato Finkelstein.   

Abstract

BACKGROUND: Carbapenem resistance among isolates of Klebsiella pneumoniae has been unusual.
OBJECTIVES: To identify risk factors for infection with carbapenem-resistant K. pneumoniae (CRKP) and to characterize microbiological aspects of isolates associated with these infections.
DESIGN: Retrospective case-control study.
SETTING: A 900-bed tertiary care hospital.
RESULTS: From January 2006 through April 2007, K. pneumoniae was isolated from 461 inpatients; 88 had CRKP infection (case patients), whereas 373 had carbapenem-susceptible K. pneumoniae infection (control subjects). The independent risk factors for infection with CRKP were prior fluoroquinolone use (odds ratio [OR], 1.87 [95% confidence interval [CI], 1.07-3.26]; P=.026), previous receipt of a carbapenem drug (OR, 1.83 [95% CI, 1.02-3.27]; P=.042), admission to the intensive care unit (OR, 4.27 [95% CI, 2.49-7.31]; P<.001), and exposure to at least 1 antibiotic drug before isolation of K. pneumoniae (OR, 3.93 [95% CI, 1.15-13.47]; P=.029). All CRKP isolates carried the bla(KPC) gene. Approximately 90% of the tested isolates carried the bla(KPC-2) allele, suggesting patient-to-patient transmission. Almost all CRKP isolates were resistant to all antibiotics, except to colistin (resistance rate, 4.5%), gentamicin (resistance rate, 7%), and tigecycline (resistance rate, 15%).
CONCLUSIONS: CRKP should be regarded as an emerging clinical threat. Because these isolates are resistant to virtually all commonly used antibiotics, control of their spread is crucial.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19496647     DOI: 10.1086/598244

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  69 in total

1.  The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae.

Authors:  Meredith G Jernigan; Ellen G Press; M Hong Nguyen; Cornelius J Clancy; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

Review 2.  Bloodstream infections in the Intensive Care Unit.

Authors:  Matteo Bassetti; Elda Righi; Alessia Carnelutti
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

3.  Differential characteristics of healthcare-associated compared to community-acquired febrile urinary tract infections in males.

Authors:  A Smithson; J Ramos; M T Bastida; S Bernal; N Jove; E Niño; N Msabri; R Porrón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-09-25       Impact factor: 3.267

4.  Molecular epidemiology, sequence types, and plasmid analyses of KPC-producing Klebsiella pneumoniae strains in Israel.

Authors:  Azita Leavitt; Yehuda Carmeli; Inna Chmelnitsky; Moran G Goren; Itzhak Ofek; Shiri Navon-Venezia
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

5.  Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals.

Authors:  D Delle Rose; P Pezzotti; E Fortunato; P Sordillo; S Gini; S Boros; M Meledandri; M T Gallo; G Prignano; R Caccese; M D'Ambrosio; G Citterio; M Rocco; F Leonardis; S Natoli; C Fontana; M Favaro; M G Celeste; T Franci; G P Testore; M Andreoni; L Sarmati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-06       Impact factor: 3.267

6.  Case-case-control study of patients with carbapenem-resistant and third-generation-cephalosporin-resistant Klebsiella pneumoniae bloodstream infections.

Authors:  Jason C Gallagher; Safia Kuriakose; Kevin Haynes; Peter Axelrod
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

7.  Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae.

Authors:  Catharine C Bulik; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

Review 8.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

Review 9.  Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.

Authors:  L S Tzouvelekis; A Markogiannakis; M Psichogiou; P T Tassios; G L Daikos
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

10.  The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies.

Authors:  Michael J Satlin; Stephen G Jenkins; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2014-01-23       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.